{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=26", "query": { "condition": "Advanced Stage Solid Tumors", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 3078, "total_pages": 308, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Stage+Solid+Tumors&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T19:22:46.214Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00448396", "title": "Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignancies" ], "interventions": [ { "name": "Patupilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2007-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-11-19", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00448396" }, { "nct_id": "NCT07205718", "title": "A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "TAK-188", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 273, "start_date": "2025-11-19", "completion_date": "2029-12-21", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 15, "location_summary": "Santa Monica, California • New Haven, Connecticut • Orlando, Florida + 12 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07205718" }, { "nct_id": "NCT03102320", "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Anetumab ravtansine (BAY94-9343)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2017-05-26", "completion_date": "2021-07-26", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Los Angeles, California • Stanford, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03102320" }, { "nct_id": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Non-Hodgkin Lymphoma", "Histiocytic Sarcoma", "Juvenile Xanthogranuloma", "Langerhans Cell Histiocytosis", "Malignant Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Ependymoma", "Recurrent Ewing Sarcoma", "Recurrent Glioma", "Recurrent Hepatoblastoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Primary Central Nervous System Neoplasm", "Recurrent Rhabdoid Tumor", "Recurrent Soft Tissue Sarcoma", "Refractory Ewing Sarcoma", "Refractory Glioma", "Refractory Hepatoblastoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Primary Central Nervous System Neoplasm", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Rhabdoid Tumor", "Stage III Osteosarcoma AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IV Osteosarcoma AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Osteosarcoma AJCC v7", "Stage IVB Osteosarcoma AJCC v7", "Wilms Tumor" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ensartinib", "type": "DRUG" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mutation Carrier Screening", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Samotolisib", "type": "DRUG" }, { "name": "Selpercatinib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Tipifarnib", "type": "DRUG" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 1377, "start_date": "2017-07-31", "completion_date": "2027-01-06", "has_results": true, "last_update_posted_date": "2026-11-13", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03155620" }, { "nct_id": "NCT00003742", "title": "Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-10", "completion_date": "2001-08", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003742" }, { "nct_id": "NCT02428712", "title": "A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Unresectable Solid Tumors", "BRAF-mutated Tumors" ], "interventions": [ { "name": "FORE8394", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fore Biotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 113, "start_date": "2015-04", "completion_date": "2024-07-12", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 13, "location_summary": "Scottsdale, Arizona • Orange, California • Stanford, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02428712" }, { "nct_id": "NCT00058253", "title": "Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Prostate Cancer", "Stage IV Prostate Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-02", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2014-06-17", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058253" }, { "nct_id": "NCT02324257", "title": "A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "RO6958688", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2014-12-30", "completion_date": "2019-09-03", "has_results": false, "last_update_posted_date": "2020-04-17", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 9, "location_summary": "Los Angeles, California • Palo Alto, California • Santa Monica, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02324257" }, { "nct_id": "NCT02705105", "title": "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Cancer", "Carcinoma", "Hepatocellular Carcinoma", "HCC" ], "interventions": [ { "name": "Mogamulizumab + Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Kyowa Kirin, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2016-02", "completion_date": "2018-10-10", "has_results": true, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 15, "location_summary": "Gilbert, Arizona • Greenbrae, California • Los Angeles, California + 12 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02705105" }, { "nct_id": "NCT07439094", "title": "A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "CKD-703", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chong Kun Dang Pharmaceutical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 140, "start_date": "2026-04-16", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-11-15T19:22:46.214Z", "location_count": 1, "location_summary": "Ohio City, Ohio", "locations": [ { "city": "Ohio City", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07439094" } ] }